LEXX

Lexaria Bioscience Corp. (LEXX) | Rumor.io

Lexaria Bioscience

LEXX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,349

Bullish sentiment (50-day avg)85%

Price to earnings ratio-0.33

Market capitalization6.8M

Earnings per share-5.13

Dividend yield (TTM)—

Revenue (annual)705.9K

Net income (annual)-11.9M

Social

What share of all stock conversation is about LEXX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 17

Lexaria Bioscience Corp. (LEXX) has seen significant absorption improvements in its 2026 animal study, with DehydraTECH 3.0 amycretin tablet formulation more than doubling absolute bioavailability and DehydraTECH 3.0 retatrutide tablet formulation increasing drug absorption by up to 4,552%.
The company's Q4 human study results are expected to be delayed to 2027, and some investors are concerned about the lack of commercial validation from big pharma.
Despite the challenges, some analysts believe that Lexaria's platform is poised for a 50m market capitalization easily, and that a commercial licensing deal with a big pharma company could be on the horizon, which could validate the platform and boost the stock price.

Generated by AI

Sentiment

Of the messages about LEXX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	70% +4.04	69.44% -26.89	83.04% -4.42
Bearish	—	30% -4.04	30.56% +26.89	16.96% +4.42

Bullish· Aug 18

The market is showing strong interest in Lexaria Bioscience Corp. ($LEXX) with recent MTA announcements and data drops expected to bring significant price movements.
The company's CEO has been accurate in recent statements, and the business development room is buzzing with potential new irons in the fire, which is being reflected in the stock's price.
The stock has strong bid stacking and is close to hyperbolic momentum, with some analysts predicting a close to $14 finish for the day.

Bearish· Sep 10

The company's stock has experienced a 70% drawdown, with some users suggesting that institutional traders are manipulating the market to create a buying opportunity.
The company's studies and partnerships have been deemed a failure, with one user stating that the CEO has been paid over $1.2 million for zero commercial deals.
The company's stock has been trading at cash value, with some users suggesting that the management team will let institutional traders cover their short positions before releasing any positive news, potentially allowing the stock to sink further.

Generated by AI

Topics

Of the messages about LEXX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	64.95%	72.68%
Technical Analysis	—	100%	28.87%	24.75%
Analysts	—	0%	6.19%	1.13%
Controversies	—	0%	0%	0.82%
Earnings	—	0%	0%	0.13%
Macro	—	0%	0%	0.5%

Announcements· Dec 23

Lexaria Bioscience Corp. ($LEXX) has achieved the primary endpoint in its Phase 1b study, GLP-1-H24-4, demonstrating superiority in reducing unwanted side effects compared to the approved oral-based GLP-1 medication, Rybelsus.
The company's DehydraTECH drug delivery technology is poised for a breakout, with a strong short-term trend and upcoming GLP-1 clinical results expected in Q4.
Lexaria's drug delivery platform ($LEXX) is well-positioned to benefit from the approval of oral GLP-1 drugs, with clinical results expected in Q4 that could drive significant upside in the stock.

Technical Analysis· Apr 14

$LEXX held up well despite stop loss raids, with a 3.56 entry point and potential for a monster day on Monday.
The stock formed a nasty ascending triangle, and a 4.50 candle close suggests further upside, potentially reaching 4.70-5.00.
$LEXX is still above its daily VWAP, and persistence can break resistance, with the 200 SMA around 5.20 as a potential target.

Generated by AI

Community

Of the messages about LEXX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	89.47%	89.08%	79.7%
Newcomers	0%	10.53%	10.92%	20.3%

Regulars· Sep 17

The regulars are focusing on the recent $7.9 million cash raise and the company's shift to transfer R&D costs onto partners via out-licensing deals, which they see as a positive development.
The price has been moving up, with the stock currently trading at around $3.29, and the regulars believe this is a good time to buy, with the bottoming process being a good place to accumulate shares.
The company's recent financial position update and the upcoming catalysts, including preclinical animal study readouts and human study results, are being closely watched by the regulars, with some seeing this as a critical turning point for the stock.

Newcomers· Dec 23

Newcomers are focusing on the strong short-term trend and potential breakout for Lexaria Bioscience Corp. ($LEXX), driven by its DehydraTECH drug delivery technology.
The approval of oral GLP-1 drugs by Novo Nordisk ($NVO) has validated the market and put a spotlight on drug delivery platforms, with Lexaria Bioscience Corp. ($LEXX) expected to release its GLP-1 clinical results in Q4.
Lexaria Bioscience Corp. ($LEXX) is poised to unlock billions by improving oral GLP-1 delivery, leveraging its DehydraTECH technology to overcome friction in the market and potentially rerating the stock.

Generated by AI

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.

13d agoYahoo Finance

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.

20d agoca.finance.yahoo.com

LEXX: Introducing DehydraTECH 3.0

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH NOTE Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated, measuring tablets and capsules as well as DehydraTECH

22d agoYahoo Finance

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise

22d agoYahoo Finance

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.

25d agoYahoo Finance

Also Discussed

Investors talking about LEXX also mention

#	Name	Attention
1	Lixte Biotechnology Holdings Inc.LIXT	0%new
2	Educational Development Corp.EDUC	0%0
3	Sharps Technology Inc.STSS	0%0
4	Novo Nordisk A/S Sponsored ADRNVO	0.14%-0.03
5	ADC Therapeutics S.A.ADCT	0%0
6	Collplant Biotechnologies LtdCLGN	0%0
7	MTSR - Metsera, Inc.	——
8	Nuvation Bio Inc.NUVB	0%0
9	Rani Therapeutics Holdings, Inc. Class A Common StockRANI	0%0
10	NeoVolta Inc.NEOV	0%+0

Lexaria Bioscience Corp.

Healthcare
Biotechnology

Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients are delivered and absorbed in the body. Its core platform, DehydraTECH, is designed to enhance oral bioavailability and can be applied across a range of compounds, including cannabinoids, nicotine, vitamins, pain medications, hormones, antivirals, and other lipophilic molecules. The company works through intellectual property licensing, business-to-business product development, and research and development activities, supporting pharmaceutical, nutraceutical, and consumer health applications. Lexaria Bioscience Corp. is headquartered in Kelowna, British Columbia, Canada, and its current work centers on developing and licensing drug delivery technologies for partners seeking more efficient oral formulations and improved therapeutic performance.

Website

Location

740 McCurdy Road

Kelowna, BC, V1X 2P7

Canada

Social

What share of all stock conversation is about LEXX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 17

Lexaria Bioscience Corp. (LEXX) has seen significant absorption improvements in its 2026 animal study, with DehydraTECH 3.0 amycretin tablet formulation more than doubling absolute bioavailability and DehydraTECH 3.0 retatrutide tablet formulation increasing drug absorption by up to 4,552%.
The company's Q4 human study results are expected to be delayed to 2027, and some investors are concerned about the lack of commercial validation from big pharma.
Despite the challenges, some analysts believe that Lexaria's platform is poised for a 50m market capitalization easily, and that a commercial licensing deal with a big pharma company could be on the horizon, which could validate the platform and boost the stock price.

Generated by AI

Sentiment

Of the messages about LEXX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	70% +4.04	69.44% -26.89	83.04% -4.42
Bearish	—	30% -4.04	30.56% +26.89	16.96% +4.42

Bullish· Aug 18

The market is showing strong interest in Lexaria Bioscience Corp. ($LEXX) with recent MTA announcements and data drops expected to bring significant price movements.
The company's CEO has been accurate in recent statements, and the business development room is buzzing with potential new irons in the fire, which is being reflected in the stock's price.
The stock has strong bid stacking and is close to hyperbolic momentum, with some analysts predicting a close to $14 finish for the day.

Bearish· Sep 10

The company's stock has experienced a 70% drawdown, with some users suggesting that institutional traders are manipulating the market to create a buying opportunity.
The company's studies and partnerships have been deemed a failure, with one user stating that the CEO has been paid over $1.2 million for zero commercial deals.
The company's stock has been trading at cash value, with some users suggesting that the management team will let institutional traders cover their short positions before releasing any positive news, potentially allowing the stock to sink further.

Generated by AI

Topics

Of the messages about LEXX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	64.95%	72.68%
Technical Analysis	—	100%	28.87%	24.75%
Analysts	—	0%	6.19%	1.13%
Controversies	—	0%	0%	0.82%
Earnings	—	0%	0%	0.13%
Macro	—	0%	0%	0.5%

Announcements· Dec 23

Lexaria Bioscience Corp. ($LEXX) has achieved the primary endpoint in its Phase 1b study, GLP-1-H24-4, demonstrating superiority in reducing unwanted side effects compared to the approved oral-based GLP-1 medication, Rybelsus.
The company's DehydraTECH drug delivery technology is poised for a breakout, with a strong short-term trend and upcoming GLP-1 clinical results expected in Q4.
Lexaria's drug delivery platform ($LEXX) is well-positioned to benefit from the approval of oral GLP-1 drugs, with clinical results expected in Q4 that could drive significant upside in the stock.

Technical Analysis· Apr 14

$LEXX held up well despite stop loss raids, with a 3.56 entry point and potential for a monster day on Monday.
The stock formed a nasty ascending triangle, and a 4.50 candle close suggests further upside, potentially reaching 4.70-5.00.
$LEXX is still above its daily VWAP, and persistence can break resistance, with the 200 SMA around 5.20 as a potential target.

Generated by AI

Community

Of the messages about LEXX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	89.47%	89.08%	79.7%
Newcomers	0%	10.53%	10.92%	20.3%

Regulars· Sep 17

The regulars are focusing on the recent $7.9 million cash raise and the company's shift to transfer R&D costs onto partners via out-licensing deals, which they see as a positive development.
The price has been moving up, with the stock currently trading at around $3.29, and the regulars believe this is a good time to buy, with the bottoming process being a good place to accumulate shares.
The company's recent financial position update and the upcoming catalysts, including preclinical animal study readouts and human study results, are being closely watched by the regulars, with some seeing this as a critical turning point for the stock.

Newcomers· Dec 23

Newcomers are focusing on the strong short-term trend and potential breakout for Lexaria Bioscience Corp. ($LEXX), driven by its DehydraTECH drug delivery technology.
The approval of oral GLP-1 drugs by Novo Nordisk ($NVO) has validated the market and put a spotlight on drug delivery platforms, with Lexaria Bioscience Corp. ($LEXX) expected to release its GLP-1 clinical results in Q4.
Lexaria Bioscience Corp. ($LEXX) is poised to unlock billions by improving oral GLP-1 delivery, leveraging its DehydraTECH technology to overcome friction in the market and potentially rerating the stock.

Generated by AI

Lexaria Bioscience

Social

Sep 17

Bullish· Aug 18

Bearish· Sep 10

Announcements· Dec 23

Technical Analysis· Apr 14

Regulars· Sep 17

Newcomers· Dec 23

Lexaria Bioscience raises $7.9M, extends cash runway to 2027

Lexaria Updates Financial Position

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

LEXX: Introducing DehydraTECH 3.0

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Lexaria Bioscience Corp.

Company Information

Location

Lexaria Bioscience raises $7.9M, extends cash runway to 2027

Lexaria Updates Financial Position

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

LEXX: Introducing DehydraTECH 3.0

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Social

Sep 17

Bullish· Aug 18

Bearish· Sep 10

Announcements· Dec 23

Technical Analysis· Apr 14

Regulars· Sep 17

Newcomers· Dec 23